SUBKLINIK GIPOTERIOZ KASALLIGINI DAVOLASHDA D VITAMININING AHAMIYATI
Keywords:
Kalit so‘zlar: subklinik gipoterioz, nevrologik buzilishlar, vitamin D, bosh og‘rig‘i, bosh aylanishi, nedokrinologik kasalliklar.Abstract
Annotatsiya
Qalqonsimon bez organizmda metabolizm, o‘sish va rivojlanishda muhim rol
o‘ynaydigan gormonlarni ishlab chiqaradi. Subklinik gipoterioz (SG) — bu
qalqonsimon bezning yengil darajadagi yetishmovchiligi bo‘lib, laborator
tekshiruvlarda TSH darajasining oshishi, ammo T3 va T4 gormonlarining normal
darajada qolishi bilan tavsiflanadi [2]. SG ko‘pincha simptomlar bilan kechmasligi
sababli aniqlanmasdan qolishi mumkin, ammo uzoq muddatda yurak-qon tomir
kasalliklari, depressiya, lipid metabolizmi buzilishiga sabab bo‘lishi ma’lum [1].
So‘nggi yillarda D vitamini yetishmovchiligi va qalqonsimon bez kasalliklari
o‘rtasidagi aloqalar keng tadqiq etilmoqda. D vitamini immunomodulyator xususiyatga
ega bo‘lib, autoimmun tiroid kasalliklarining rivojlanishi va davrida muhim rol
o‘ynashi mumkin [6]. Ushbu maqolada SG kasalligida D vitamini roli, uning klinik
ahamiyati va davolashdagi o‘rni batafsil tahlil qilinadi.
References
Foydalanilgan adabiyotlar
1. Biondi, B., & Cooper, D. S. (2019). The clinical significance of subclinical thyroid
dysfunction. *Endocrine Reviews*, 40(1), 105-130.
2. Canaris, G. J., et al. (2000). The Colorado thyroid disease prevalence study.
*Archives of Internal Medicine*, 160(4), 526-534.
3. Caturegli, P., et al. (2014). Hashimoto thyroiditis: clinical and diagnostic criteria.
*Autoimmunity Reviews*, 13(4-5), 391-397.
4. Cellini, M., et al. (2017). Vitamin D receptor and thyroid function. *Journal of
Endocrinological Investigation*, 40(1), 1-7.
5. Choi, Y. J., et al. (2019). Effects of vitamin D supplementation on autoimmune
thyroid disease: a meta-analysis. *Endocrine*, 65(1), 73-80.
6. D’Aurizio, F., et al. (2015). Vitamin D and subclinical hypothyroidism: a clinical
trial. *Thyroid Research*, 8(1), 1-7.
7. Dankers, W., et al. (2017). Vitamin D in autoimmunity: molecular mechanisms and
therapeutic potential. *Frontiers in Immunology*, 7, 697.
8. Dawson-Hughes, B. (2012). Vitamin D and health outcomes. *Clinical Chemistry*,
58(3), 415-423.
9. Gharib, H., et al. (2000). Subclinical hypothyroidism: a review. *JAMA*, 283(10),
1226-1233.
10. Abdukadirova, D. T., Umarova, M., & Marupov, A. (2022). Binsvanger kasalligi
asoratlari profilaktikasi. INNOVATION IN THE MODERN EDUCATION
SYSTEM, 2(24), 94-97.
11. Holick, M. F. (2011). Vitamin D: evolutionary, physiological and health
perspectives. *Current Drug Targets*, 12(1), 4-18.
12. Abdumuxtor o‘g‘li, M. D., & Abrorjon Toshturg‘un o‘g, M. (2024). ALSGEYMER
KASALLIGINING KELIB CHIQISHI, SABABLARI, BOSQICHLARI VA
DAVOLASH USULLARINI OPTIMALLASHTIRISH. AMERICAN JOURNAL
OF APPLIED MEDICAL SCIENCE, 2(4), 26-30.
13. Prietl, B., et al. (2013). Vitamin D and immune function. *Nutrients*, 5(7), 2502-
2521.
14. Abrorjon, M. (2024). AGE-RELATED FEATURES OF TENSION HEADACHES
IN CHILDREN AND ADOLESCENTS. PEDAGOG, 7(6), 395-398.
15. Ross, A. C., et al. (2011). The 2011 report on dietary reference intakes for calcium
and vitamin D. *Journal of Clinical Endocrinology & Metabolism*, 96(1), 53-58.
16. Vanderpump, M. P. (2011). The epidemiology of thyroid disease. *British Medical
Bulletin*, 99, 39-51.
17. Abrorjon Toshturg’un o’g, M., & Abdukarimjon, M. (2023). Prevention of
Consequences of Binswanger's Disease. American Journal of Pediatric Medicine
and Health Sciences (2993-2149), 1(10), 425-427.
